Correlation between HLA alleles and EGFR mutation in japanese patients with adenocarcinoma of the lung

Journal of Thoracic Oncology

Volumn 5, Issue 8, 2010, Pages 1136-1142

  Uramoto, Hidetaka ^a   So, Tomoko ^a   Nagata, Yoshika ^a   Kuroda, Koji ^a   Shigematsu, Yoshiki ^a   Baba, Tetsuro ^a   So, Tetsuya ^a   Takenoyama, Mitsuhiro ^a   Hanagiri, Takeshi ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Adenocarcinoma; EGFR; HLA; Surgical resection

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; HLA A ANTIGEN; HLA A11 ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A26 ANTIGEN; HLA A31 ANTIGEN; HLA A33 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA B35 ANTIGEN; HLA B44 ANTIGEN; HLA B46 ANTIGEN; HLA B51 ANTIGEN; HLA B52 ANTIGEN; HLA B60 ANTIGEN; HLA B61 ANTIGEN; HLA B62 ANTIGEN; HLA B7 ANTIGEN; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CYTOTOXICITY TEST; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; HISTOGENESIS; HLA SYSTEM; HUMAN; HUMAN CELL; INTRON; JAPANESE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; SMOKING;

EID: 77955092394     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e0b993     Document Type: Article

References (49)

1. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell 2002;1:49-52.
2. Janssen-Heijnen ML, Coebergh JW. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 2001;31:123-137.
3. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-719. (Pubitemid 33040631)
4. Asamura H, Goya T, Koshiishi Y, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008;3:46-52.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
8. Uramoto H, Sugio K, Oyama T, et al. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 2006;51:71-77.
9. Sugio K, Uramoto H, Ono K, et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006;94: 896-903.
10. Nose N, Sugio K, Oyama T, et al. Association between estrogen receptor beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of patients with adenocarcinoma of the lung. J Clin Oncol 2009;27:411-417.
11. Mandelboim O, Reyburn HT, Vales-Gomez M, et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 1996;184:913-922.
12. Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: genes involved and possible mechanisms. Transpl Immunol 2005;14:175-182.
13. So T, Takenoyama M, Sugaya M, et al. Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 2001;32:39-46.
14. Nagata Y, Hanagiri T, Mizukami M, et al. Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan. Lung Cancer 2009;65:91-97.
15. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000;18:106-115.
16. Terasaki PI, Mcclelland JD. Microdroplet assay of human serum cyto- toxins. Nature 1964;204:998-1000.
17. Marsh SG, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2004. Tissue Antigens 2005;65:301-369.
18. Saito S, Ota S, Yamada E, et al. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 2000;56:522-529.
19. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346. (Pubitemid 40425952)
20. Ellis JM, Henson V, Slack R, et al. Frequencies of HLA-A2 alleles in five U.S. population groups: Predominance of A*02011 and identification of HLA-A*0231. Hum Immunol 2000;61:334-340.
21. Cao K, Hollenbach J, Shi X, et al. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001;62:1009-1030.
22. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-8203.
23. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520.
24. Shimura T, Hagihara M, Takebe K, et al. The study of tumor necrosis factor beta gene polymorphism in lung cancer patients. Cancer 1994; 73:1184-1188.
25. Ichiki Y, Takenoyama M, Mizukami M, et al. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 2004;172:4844-4850.
26. So T, Takenoyama M, Mizukami M, et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005;65:5945-5952.
27. Nagata Y, Hanagiri T, Takenoyama M, et al. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient. Clin Cancer Res 2005;11:5265-5272.
28. Takenoyama M, Baurain JF, Yasuda M, et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 2006;118:1992-1997.
29. Fukuyama T, Hanagiri T, Takenoyama M, et al. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res 2006;66:4922-4928.
30. Sugaya M, Takenoyama M, Shigematsu Y, et al. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. Int J Cancer 2007;120:1055-1062.
31. Baba T, Hanagiri T, Ichiki Y, et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci 2007;98:1795-1802.
32. Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005;65:5076-5083.
33. Suzuki H, Takahashi T, Kuroishi T, et al. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992;52:734-736.
34. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92:1525-1530.
35. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923.
36. Sueoka-Aragane N, Imai K, Komiya K, et al. Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1. Cancer Sci 2008;99:1180-1187.
37. Matsuo K, Ito H, Yatabe Y, et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 2007;98:96-101.
38. Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001;61:2799-2803.
39. Ko YC, Cheng LS, Lee CH, et al. Chinese food cooking and lung cancer in women nonsmokers. Am J Epidemiol 2000;151:140-147.
40. Matsuo K, Hiraki A, Ito H, et al. Soy consumption reduces the risk of non-small-cell lung cancers with epidermal growth factor receptor mutations among Japanese. Cancer Sci 2008;99:1202-1208.
41. Gazdar AF. Activating and resistance mutations of EGFR in non-small- cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28:S24-S31.
42. Marks JL, Golas B, Kirchoff T, et al. EGFR mutant lung adenocarcino- mas in patients with germline BRCA mutations. J Thorac Oncol 2008; 3:805.
43. Ludwig T, Fisher P, Ganesan S, et al. Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev 2001;15:1188-1193.
44. Yuan Z, Shin J, Wilson A, et al. An A13 repeat within the 3'- untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. Cancer Res 2009;69:7811-7818.
45. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. JClin Oncol 2003;21:3798-3807.
46. Modrek B, Ge L, Pandita A, et al. Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res 2009;7:1244-1252.
47. Buerger H, Packeisen J, Boecker A, et al. Allelic length of a CA dinucleotide repeat in the egfrgene correlates with the frequency of amplifications of this sequence-first results of an inter-ethnic breast cancer study. J Pathol 2004;203:545-550.
48. Wong MP, Lam WK, Wang E, et al. Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. Cancer Res 2002;62:4464-4468.
49. Wei EX, Anga AA, Martin SS, et al. EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimens. Mod Pathol 2007;20:905-913.